Related Experiment Video
Updated: Apr 23, 2026
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
A549 cell proliferation inhibited by RNAi mediated silencing of the Nrf2 gene
Bo Zhang1, Chen Xie2, Jing Zhong2
1Key Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education, Shihezi 832002, China Pharmacology Department, School of Pharmacy, Shihezi University, Shihezi 832002, China.
Abstract:
Non-small-cell lung cancer (NSCLC), the most common type of lung cancers, is resistant to initial chemotherapy intrinsically. The expressions of xenobiotic metabolism genes, antioxidants, and drug efflux proteins are increased in NSCLC. In addition, a redox-sensitive transcription factor named Nrf2 regulates the drug resistance via the expression of electrophile, oxidants detoxification enzymes and efflux mechanism. As was detected by real-time PCR, inhibiting Nrf2 expression through the transfection of shRNA plasmids in A549 cells significantly inhibits the expressions of glutathione pathway genes, antioxidants and multidrug resistance proteins. Using biochemical assays and free radical medical experiments in vitro, it was identified that the RNAi-mediated reduction of Nrf2 expression in lung cancer cells induces the generation of reactive oxygen species, decreases the level of reduced glutathione and results in an increase in the A549 cell proliferation inhibition rate. Thus, targeting Nrf2 activity in NSCLC could be a practical way to inhibit tumor growth and eliminate chemoresistance.
Insights
Targeting Nrf2 in non-small-cell lung cancer (NSCLC) can overcome chemotherapy resistance. Inhibiting Nrf2 reduces drug resistance mechanisms, leading to increased cancer cell death and reduced tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Non-small-cell lung cancer (NSCLC) exhibits intrinsic resistance to chemotherapy.
- Increased expression of xenobiotic metabolism genes, antioxidants, and drug efflux proteins contributes to NSCLC chemoresistance.
- The transcription factor Nrf2 plays a key role in regulating drug resistance through detoxification enzymes and efflux mechanisms.
Purpose of the Study:
- To investigate the role of Nrf2 in NSCLC chemoresistance.
- To evaluate the therapeutic potential of inhibiting Nrf2 in NSCLC.
Main Methods:
- Real-time PCR was used to detect gene expression changes.
- shRNA plasmids were transfected into A549 cells to inhibit Nrf2 expression.
- In vitro biochemical assays and free radical experiments were performed.
Main Results:
- Inhibiting Nrf2 significantly reduced the expression of glutathione pathway genes, antioxidants, and multidrug resistance proteins.
- Nrf2 reduction induced reactive oxygen species generation and decreased reduced glutathione levels.
- A549 cell proliferation inhibition rate increased following Nrf2 inhibition.
Conclusions:
- Nrf2 is a critical regulator of chemoresistance in NSCLC.
- Targeting Nrf2 activity presents a viable strategy to enhance chemotherapy efficacy and inhibit tumor growth in NSCLC.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...